Comments
Biocon Biologics on Thursday said it has refinanced $1.1 billion (₹9,347 crore) long-term debt through dollar bonds and new syndicated facility.
The company said the bonds will be issued by Biocon Biologics Global plc, a wholly owned subsidiary of the company, and will be backed by a strong security package, Biocon Biologics, a unit of Biocon Ltd, said in a statement.
The transaction is expected to settle on October 9, 2024, subject to customary closing conditions, it added.
"This strategic refinancing underscores our commitment to enhance financial flexibility, fuels Biocon Biologics' long-term growth and is core to the consolidation phase of our business," Biocon Biologics CEO and Managing Director Shreehas Tambe said.
The company expects the transaction to strengthen capital structure and allow it to redeploy investments into the business, including advancing our differentiated pipeline of biosimilars, he added.
"It will also enable us to diversify our investor base to include marquee global funds and healthcare investors who seek to participate in Biocon Biologics' growth story," Tambe said.
Shares of Biocon were trading 0.81 per cent down at ₹367.40 apiece on BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.